FDA Gives Tentative Approval to Generic Twice-Yearly HIV Prevention Injection at $40 a Year

The U.S. Food and Drug Administration granted tentative approval on November 2, 2026, to the first generic version of lenacapavir, a twice-yearly injectable for HIV prevention, manufactured by India's Dr. Reddy's Laboratories.

The approval covers use in 120 low- and middle-income countries under Gilead Sciences' voluntary licensing program. The expected price is $40 per person per year, matching the cost of daily oral PrEP tablets currently available. The originator product, marketed by Gilead as Yeztugo in the United States, carries a list price of $28,218 per year.

Tentative approval is the FDA's standard designation while the innovator patent remains in force. It does not authorize sales inside the United States but qualifies the product for purchase by the U.S. government and accelerates regulatory review in other countries. The originator received full FDA approval for prevention in June 2025. The generic arrived 16 months later.

Lenacapavir works by inhibiting the HIV capsid protein. Two large clinical trials showed it reduced new infections by more than 99 percent among people at high risk when given every six months. The long interval removes the need for daily pills, which improves adherence in settings where clinic visits or consistent medication access is difficult.

Global health organizations including Unitaid, the Clinton Health Access Initiative, and Wits RHI brokered an early pricing and supply agreement with Dr. Reddy's in September 2025. The companies and partners accelerated development and regulatory work. Initial shipments are expected to reach countries before the end of 2026. Zambia is among the first destinations, with broader availability projected for 2027. More than 125,000 people in Africa have already started on the originator version.

Neil Buddy Shah, CEO of the Clinton Health Access Initiative, said the 16-month timeline from originator approval to generic shows what is possible when access is prioritized from the start. Demand for the originator has already exceeded supply in some low-income markets. The generic is intended to close that gap.

The FDA reviewed the product under the President's Emergency Plan for AIDS Relief pathway, which has long been used to verify quality of HIV medicines destined for other countries. An FDA tentative approval often speeds national approvals elsewhere and can support World Health Organization prequalification.

Gilead retains patent protection in high-income markets. The company has said the U.S. list price is comparable to other PrEP options after accounting for insurance and assistance programs. In lower-income countries the $40 annual figure is designed to be sustainable for public programs and donor-funded efforts.

HIV prevention tools have expanded from daily pills to long-acting injectables. Lenacapavir is the first twice-yearly option. Earlier long-acting cabotegravir requires dosing every two months. The longer interval reduces clinic burden and the risk of missed doses. Modeling studies suggest that scaling twice-yearly prevention at low cost could substantially cut new infections in high-burden regions if supply and delivery systems keep pace.

Dr. Reddy's is one of the world's largest generic manufacturers. The company has stated it will begin shipping next month as part of the multi-partner effort. Regulatory authorities in recipient countries will still need to complete their own reviews, though the FDA step removes a major barrier.

The approval does not change access inside the United States, where the branded product remains the only option. Advocates have pressed for lower U.S. pricing and broader insurance coverage. The global arrangement, however, targets the countries that account for the large majority of new infections.

Public health officials will track how quickly the generic moves from manufacturing sites to clinics and how many additional people start prevention. The six-month schedule also changes logistics: cold-chain requirements, injection training, and follow-up systems must be adapted for larger volumes.